Citius Pharmaceuticals Inc. held a special meeting of stockholders on June 9, 2025. At the meeting, stockholders approved an amendment to increase the authorized number of shares of capital stock from 26,000,000 to 260,000,000 and the authorized number of common shares from 16,000,000 to 250,000,000. Additionally, an adjournment proposal was rendered moot due to the approval of the amendment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.